Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
27 hedge funds and large institutions have $592K invested in Vyant Bio, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 26 → 27 (+1)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
86% less capital invested
Capital invested by funds: $4.26M → $592K (-$3.66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$131K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$64.3K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$18.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$639K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$488K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$198K |
| 4 |
FCM
Fairbanks Capital Management
Rancho Santa Fe,
California
|
-$79.3K |
| 5 |
VF
Virtu Financial
New York
|
-$47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | -$1.52K | -18 | -72% |
|
27
Group One Trading
Chicago,
Illinois
| – | +$84 | +1 | New |
|
28
JP Morgan Chase
New York
| – | +$421 | +5 | New |
|
VYNT Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2018, worth a combined $592K — down 86% from $4.26M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VYNT positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $131K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $639K sold.
- 27 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2018, up from 26 in Q3 2018.
- Funds reported $592K of Vyant Bio, Inc. Common Stock stock for Q4 2018, down 86% quarter-over-quarter.
- 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +2 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $131K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2018 was Stonepine Capital Management, an estimated $639K sold.
Based on aggregated 13F filings for Q4 2018.